EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plasma Alzheimer's disease biomarker variability: Amyloid‐independent and amyloid‐dependent factors

Eun Hye Lee, Sung Hoon Kang, Daeun Shin, Young Ju Kim, Henrik Zetterberg, Kaj Blennow, Fernando Gonzalez-Ortiz, Nicholas J Ashton, Bo Kyoung Cheon, Heejin Yoo, Hongki Ham, Jihwan Yun und 6 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.14368 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Eun Hye Lee und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Amyloid beta-Peptides. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Kirsten og Freddy Johansens Fond, Korea University Guro Hospital, Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION We aimed to investigate which factors affect plasma biomarker levels via amyloid beta (Aβ)‐independent or Aβ‐dependent effects and improve the predictive performance of these biomarkers for Aβ positivity on positron emission tomography (PET). METHODS A total of 2935 participants underwent blood sampling for measurements of plasma Aβ42/40 ratio, phosphorylated tau 217 (p‐tau217; ALZpath), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) levels using single‐molecule array and Aβ PET. Laboratory findings were collected using a routine blood test battery. RESULTS Aβ‐independent factors included hemoglobin and estimated glomerular filtration rate (eGFR) for p‐tau217 and hemoglobin, eGFR, and triiodothyronine (T 3 ) for GFAP and NfL. Aβ‐dependent factors included apolipoprotein E genotypes, body mass index status for Aβ42/40, p‐tau217, GFAP, and NfL. However, these factors exhibited negligible or modest effects on Aβ positivity on PET. DISCUSSION Our findings highlight the importance of accurately interpreting plasma biomarkers for predicting Aβ uptake in real‐world settings. Highlights We investigated factor–Alzheimer's disease plasma biomarker associations in a large Korean cohort. Hemoglobin and estimated glomerular filtration rate affect the biomarkers independently of brain amyloid beta (Aβ). Apolipoprotein E genotypes and body mass index status affect the biomarkers dependent on brain Aβ. Addition of Aβ‐independent factors shows negligible effect in predicting Aβ positivity. Adjusting for Aβ‐dependent factors shows a modest effect in predicting Aβ positivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBiomarkersAmyloid beta-PeptidesHumansMaleFemaletau ProteinsPositron-Emission TomographyAgedGlial Fibrillary Acidic ProteinNeurofilament ProteinsPeptide FragmentsMiddle AgedApolipoproteins E

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid beta–dependent variabilityamyloid beta–independent variabilitybiomarker applicationbiomarker variabilitycomorbidityplasma biomarkerssubcortical vascular cognitive impairment

Substanzen

BiomarkersAmyloid beta-Peptidestau ProteinsGlial Fibrillary Acidic ProteinNeurofilament Proteinsneurofilament protein LPeptide FragmentsApolipoproteins EGFAP protein, human

Autor:innen und Institutionen

  • Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea.
  • Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, South Korea.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Göteborg, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Göteborg, Sweden.
  • Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.

Förderung

  • Kirsten og Freddy Johansens Fond
  • Korea University Guro Hospital
  • Swedish Research Council
  • NIA NIH HHS
  • Alzheimer's Association
  • Swedish Alzheimer Foundation
  • Ministry of Health & Welfare and Ministry of Science and ICT
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Lee, E. H., Kang, S. H., Shin, D., Kim, Y. J., Zetterberg, H., Blennow, K., Gonzalez-Ortiz, F., Ashton, N. J., Cheon, B. K., Yoo, H., Ham, H., Yun, J., Kim, J. P., Kim, H. J., Na, D. L., Jang, H., Seo, S. W., & K‐ROAD study group (2025). Plasma Alzheimer's disease biomarker variability: Amyloid‐independent and amyloid‐dependent factors. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14368

Vancouver

Lee EH, Kang SH, Shin D, Kim YJ, Zetterberg H, Blennow K, et al. Plasma Alzheimer's disease biomarker variability: Amyloid‐independent and amyloid‐dependent factors. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14368

BibTeX
@article{Lee2025,
  author = {Lee, Eun Hye and Kang, Sung Hoon and Shin, Daeun and Kim, Young Ju and Zetterberg, Henrik and Blennow, Kaj and Gonzalez-Ortiz, Fernando and Ashton, Nicholas J and Cheon, Bo Kyoung and Yoo, Heejin and Ham, Hongki and Yun, Jihwan and Kim, Jun Pyo and Kim, Hee Jin and Na, Duk L and Jang, Hyemin and Seo, Sang Won and K‐ROAD study group, K‐ROAD study group},
  title = {Plasma Alzheimer's disease biomarker variability: Amyloid‐independent and amyloid‐dependent factors},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.14368}
}
Kostenlos starten →